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Abstract
Synovial fibroblasts occur as two phenotypes – intimal and subintimal. The specialised
intimal phenotype includes expression of uridine diphosphoglucose dehydrogenase
(UDPGD), vascular cell adhesion molecule-1 (VCAM-1) and complement decay-
accelerating factor (DAF). These gene products contribute to specialised functions relating
to tissue movement and leucocyte traffic.
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Introduction
To follow fibroblast nomenclature, synovial fibroblasts
should be defined as nonvascular, nonepithelial cells in
synovium that arise locally, by division, during embryogen-
esis, that are replaced by local division, and that synthe-
sise fibrous matrix proteins. Establishing cell origins and
functions is not easy, and it is not absolutely certain that
such cells even exist. There is no reliable positive fibro-
blast marker. However, circumstantial evidence suggests
that most common leucocyte antigen (CD45)-negative,
nonvascular cells in normal synovium fit the definition.
In normal human synovium, fibroblasts show two pheno-
types: intimal and subintimal [1] (Fig. 1). Intimal fibroblasts
express a specialised range of gene products, including
UDPGD, VCAM-1 and complement DAF [1–4]. The rabbit
has two intimal forms, one UDPGD-positive and one
VCAM-1-positive. In contrast, both human and rabbit
subintimal fibroblasts appear unspecialised. Intimal fibro-
blasts are known as ‘fibroblast-like’ or ‘type B’ synovio-
cytes/synovial lining cells [5]. The intimal and subintimal
fibroblasts do not remain distinct in tissue culture so the
general term ‘synovial fibroblast’ has to be applied (a
common source of confusion).
Intimal and subintimal fibroblasts may be independent
lineages, but the simplest view is of a single lineage that
can take on an intimal phenotype in response to local
stimuli. Several observations, including that of phenotypic
convergence in vitro, support this view. The local stimuli
are not known, but the intima does fail to form in
immobilised chick embryos [6].
In arthritis, defining fibroblast populations is more difficult
[1]. It is similar to watching a football game in which the
players have randomly swapped shirts. Numerous different
functions and origins have been ascribed to cell subpopu-
lations, but the picture currently remains consistent with ahttp://arthritis-research.com/content/2/5/344
single fibroblast population responding to a mixture of
normal intimal environmental signals and the signals of an
inflammatory response.
Development
In the foetus, the skeleton starts as a branching rod of
cells or blastema [7], within which foci of chondrocytes
develop to determine the sites and shapes of bones. A
continuous envelope of cells that express the hyaluronan
receptor, CD44, at high level, surrounds these cartilagi-
nous foci [8]. Where this perichondrial envelope lies
between cartilage foci, it is known as the interzone.
An interzone at the site of a synovial joint detaches itself
from the cartilage to become synovium. In sharks, that is
the end of the story but, in higher vertebrates, perichondrial
cells create another internal surface. Together with blood
vessels, they invade the cartilage shaft to create bone
marrow spaces, populated by two fibroblast-like cells:
UDPGD-positive osteoblastic cells, and VCAM-1-positive
cells that support leucocyte maturation (‘nurse cells’) [9,10].
There are further complexities but, in simple terms, synovial
fibroblasts appear to derive from a CD44+ perichondrial
stock that also gives rise to bone marrow stromal cells
[11]. There is also the interesting implication that the bone
marrow evolved in bony fish by putting the functional prop-
erties of synovial fibroblast precursors to new advantage.
Differentiation
Intimal fibroblast specialisation can be divided into matrix
turnover and interaction with leucocytes. Perhaps the defin-
ing feature of intimal fibroblasts is their high level of
production of hyaluronan [12], reflected in the high activity
of the enzyme UDPGD [2]. Also, molecules associated
with basal laminae, including fibronectin, type IV collagen,
laminin and chondroitin-6-sulphate-bearing proteoglycans,
and two types of microfibril, based on fibrillin-1 and type VI
collagen [13–15], surround intimal fibroblasts. Other
specialised products may include lubricin [16], phospho-
lipids [17] and unusual carbohydrate entities [18]. Normal
intimal fibroblasts have not been shown to produce matrix-
degrading enzymes in situ. However, responses to cyto-
kines in culture and in situ hybridisation studies in diseased
tissue suggest that synovial fibroblasts secrete metallo-
proteinases more readily than most other fibroblasts, and
that this may manifest itself chiefly in the intima [19,20].
Synovial fibroblasts may interact with leucocytes and
inflammatory pathways in several ways. Intimal fibroblasts
express higher levels of VCAM-1 and DAF than any cells
except bone marrow stromal cells and lymphoid follicular
dendritic cells [3,4,21]. Synovial fibroblasts can also be
induced to express complement receptor 2, normally only
present on follicular dendritic cells and B lymphocytes [21].
VCAM-1 binds to a4b1 integrin, carried on mononuclear
but not polymorphonuclear leucocytes. This probably
explains why, in synovitis, granulocytes pass into the syn-
ovial fluid but mononuclear cells tend to be retained in the
tissue. The result is different for different mononuclear cell
subgroups. Macrophages are arrested at the intima;
however, they then lose a4b1 integrin, which probably
explains why most intimal fibroblasts and macrophages
are not in contact, but separated by matrix channels that
may facilitate fluid flux. Thus, VCAM-1 does not appear to
be involved in continuing intercellular cohesion. It does not
mediate adhesion to matrix or other stromal cells, so it is
unlikely to be relevant to pathological adhesive processes.
T lymphocytes are rarely seen in the intima, even in
disease. Taken with what is known about lymphoid tissue
architecture, this suggests that, although T cells make
functional interactions with VCAM-1-positive resident
cells, most then move away. In inflamed synovium, B lym-
phocytes may be found in the intima but they are almost
invariably undergoing lysis [21]. Viable B lymphocytes are
only found in subintimal clusters associated with VCAM-1-
positive cells. This suggests that the intima is hostile to
B-lymphocyte survival, possibly because of the anti-
adhesive effect of hyaluronan.
The synovial intima shares DAF expression with coelomic
linings such as the pericardium and pleura [4]. DAF
expression at these sites is associated with local
macrophage expression of the immunoglobulin receptor
FcgRIIIa [22], and both molecules are adsorbed onto peri-
cellular fibrillin-1-based microfibrils. It seems probable that
DAF and FcgRIIIa together modulate the tissue response
Figure 1
Schematic representation of a normal synovium. The intima contains
specialised fibroblasts expressing VCAM-1, DAF and UDPGD (dark
blue), and specialised macrophages expressing FcgRIIIa (dark red).
The deeper subintima contains relatively unspecialised counterparts
(pale colours).Arthritis Research    Vol 2 No 5 Edwards
to immune complexes, possibly providing an ‘early
warning’ response for internal cavities that might be
colonised by micro-organisms.
DAF is also a coligand for the macrophage surface protein
CD97 [23]. All macrophages in the synovium express
CD97 equally, but only the intimal macrophages in contact
with DAF-coated microfibrils express FcgRIIIa, raising the
possibility that DAF and CD97 are involved in induction of
FcgRIIIa expression.
DAF protects leucocytes from physiological killing mecha-
nisms and may be important for survival at various stages
of development [24,25]. Specifically, stromal cells express
DAF at all sites where cells of the B-lymphocyte lineage
reside. Note that, both in ontogeny and phylogeny, leuco-
cyte precursors initially arise in the splanchnopleural
coelomic lining [26]. This raises the possibility that
aspects of gene regulation ‘borrowed’ from synovial
precursors in the evolution of bone marrow stroma had, in
turn, been ‘borrowed’ from the coelomic lining in the
evolution of synovium. While this begins to make sense of
the relationships between these tissues, ‘borrowing’, in
Darwinian terms, simply means the chance generation of
an advantageous overlap in lineage-specific transcriptional
regulation. It is more likely to occur in closely related
lineages, but not out of necessity.
In arthritic synovium, the intimal phenotype changes rela-
tively little. UDPGD activity is reduced in rheumatoid
tissue [2], VCAM-1 and DAF remain prominent [21,27],
while metalloproteinase production is increased but may
be very patchy [28]. The major change is in subintimal
fibroblasts, which take on intimal features. Here, there is a
modest increase in UDPGD activity [2], VCAM-1 and DAF
expression appears locally, and matches intimal levels
where B lymphocytes are present [21,27]. Moreover, if a
follicular structure is formed, these same cells express
complement receptor 2 [21] which, although inducible on
synovial fibroblasts in vitro by cytokines, is never seen in
the intima, for unknown reasons. The key signal driving
these changes appears to be tumour necrosis factor a,
although other macrophage and T-cell cytokines are prob-
ably also involved.
Pannus contains a heterogeneous mixture of cells with
intimal and subintimal features. There are also cells with
features of chondrocytes, suggesting a mixed synovial and
cartilaginous origin [29]. Pannus is probably a nonspecific
reaction to cartilage damage, since it appears both in
chemical arthritis in animals and in cartilage transplanted
into normal subcutaneous tissue [30].
Further similarities between synovial and bone marrow
fibroblasts have been observed in synovitis. Shared gene
products include bone marrow stromal factor 1, stromal
cell-derived factor 1, and bone morphogenetic protein 2
[10,31,32]. These might be interpreted as indicating influx
of bone marrow cells; in rodents, contiguity between syno-
vium and bone marrow probably does allow mixing of
populations. However, the simpler view is that synovial
and bone marrow stromal cells are derived from the same
stock and have the same potential for specialised gene
expression. The manifestation of that potential depends on
the local environment, with matrix synthetic and leucocyte
interactive factors being co-expressed at some sites
(normal human intima) but not at others (bone marrow,
rabbit intima). The further overlap of transcriptional control
with lymphoid stromal cells probably makes it relatively easy
for synovial stroma to transform into a heterogeneous
mixture of bone marrow and lymphoid environments, confer-
ring susceptibility to certain types of immune dysregulation.
Conclusion
Synovium is a highly specialised immunologic microenvi-
ronment with affinities with splanchnopleura and bone
marrow that may explain its involvement in inflammatory
rheumatic disease.
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